New drug duo targets recurrent skin cancer
NCT ID NCT05846724
Summary
This study aimed to test whether combining two existing cancer drugs (pembrolizumab and lenvatinib) could help control classic Kaposi sarcoma in people whose disease returned or didn't respond to previous chemotherapy. The trial planned to enroll adults with measurable skin lesions who had already tried at least one other treatment. The study was withdrawn before any participants were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KAPOSI SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.